Latest Janssen Inc. Stories
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV TORONTO, Sept. 17, 2014 /CNW/ - Janssen Inc.
Neuroscience Catalyst to Focus on Mood Disorders and Alzheimer's Disease TORONTO, Sept. 8, 2014 /CNW/ - Janssen Inc.
INVOKANA((TM) )offers a new approach to treatment TORONTO, May 26, 2014 /CNW/ - Janssen Inc.
- To give a box on the ear to.